Nektar Therapeutics Stock Surges 156% to 86th in Trading Volume Ranking After Eczema Treatment Breakthrough

On June 24, 2025, Nektar Therapeutics (NKTR) experienced a significant surge in trading volume, with a total turnover of $802 million, marking a 7787.54% increase from the previous day. This substantial rise placed NKTR at the 86th position in terms of trading volume for the day. The stock price of NKTR soared by 156.13%, marking its second consecutive day of gains, with a total increase of 187.13% over the past two days.

Nektar Therapeutics' stock price doubled in early trading after the company announced that it had achieved its targets in a midstage study of its eczema treatment. The Phase 2b REZOLVE-AD study, which involved 393 patients with moderate-to-severe atopic dermatitis, demonstrated statistically significant improvements in key endpoints, including the Eczema Area and Severity Score (EASI) and the Investigator’s Global Assessment for Atopic Dermatitis (vIGA-AD).

The study showed that patients receiving the investigational drug rezpegaldesleukin experienced a 53% to 61% improvement in symptoms after 16 weeks, compared to a 31% improvement in the placebo group. The high dose of rezpegaldesleukin also achieved statistical significance on EASI-90, indicating a 90% reduction in EASI from baseline. The safety profile of the drug was consistent with previously reported results, with no increased risk of conjunctivitis, oral ulcers, or infections.

Nektar Therapeutics plans to submit these findings for presentation at a medical conference later in 2025. The positive results from the REZOLVE-AD study have generated significant investor interest, driving the stock price higher and highlighting the potential of rezpegaldesleukin as a promising treatment for atopic dermatitis.